glp-1 and gallbladder GLP-1s & Gallbladder: What to Know Gallbladder Risks with GLP-1 Medications

"When we looked closely at the evidence, it became clear that risk is minimal in patients without preexisting gastric motility issues." High-risk patients such as those with diabetic gastroparesis, Parkinson's disease or a recent dose escalation may still warrant individualized precautions, according to the expert panel

Front Pharmacol 15:1347047 Nabrdalik K, Skonieczna-ydecka K, Irlik K, Hendel M, Kwiendacz H, oniewski I, Lip GY (2022) Gastrointestinal adverse events of Metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials

By reducing the degradation of GLP-1, these drugs enhance its activity, leading to increased insulin secretion, reduced glucagon levels, and improved blood sugar control

Orforglipron is being studied in adults with obesity or overweight individuals with at least one weight-related condition

Semaglutide and liraglutide usage in weight control produces sustained and meaningful weight reduction, which allows these drugs to become potential surgical alternatives for bariatric procedures in select patient groups [10,11]

Reviews focusing on semaglutide specifically [65] and broader examinations of GLP-1 RA mechanisms and clinical data have consistently concluded that these agents represent important therapeutic advances